Literature DB >> 2180707

Therapy of enterococcal infections.

G M Eliopoulos1, C T Eliopoulos.   

Abstract

Because enterococci are typically tolerant of the bactericidal effects of cell wall-active antimicrobial agents, bactericidal therapy has required use of these agents in combination with aminoglycosides. For strains which do not demonstrate high-level aminoglycoside resistance, either streptomycin or gentamicin can be used in combination with penicillin, ampicillin or vancomycin. At some centers, as many as 50% of isolates display high-level gentamicin resistance. A minority of such isolates will not be highly streptomycin-resistant, and the latter drug can be used in combination with a cell wall-active drug. Optimal treatment of serious infections due to strains highly resistant to both streptomycin and gentamicin is unknown. While no agent is predictably bactericidal against such isolates, ampicillin, penicillin or vancomycin alone would be expected to cure some patients. Other drugs or drug combinations do not offer any predictable therapeutic advantages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180707     DOI: 10.1007/BF01963636

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  77 in total

1.  The treatment of subacute bacterial endocarditis with antibiotics.

Authors:  T H HUNTER
Journal:  Am J Med       Date:  1946-07       Impact factor: 4.965

2.  The Combined Action of Penicillin with Streptomycin or Chloromycetin on Enterococci in Vitro.

Authors:  E Jawetz; J B Gunnison; V R Coleman
Journal:  Science       Date:  1950-03-10       Impact factor: 47.728

3.  A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis.

Authors:  R C Moellering; B E Murray; S C Schoenbaum; J Adler; C B Wennersten
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

4.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

5.  Antimicrobial therapy of experimental enterococcal endocarditis.

Authors:  E W Hook; R B Roberts; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

6.  Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis.

Authors:  W R Wilson; C J Wilkowske; A J Wright; M A Sande; J E Geraci
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

7.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

8.  Vancomycin-resistant Streptococcaceae from clinical material.

Authors:  R Lütticken; G Kunstmann
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1988-01

9.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

10.  Antagonistic effect of penicillin-amikacin combinations against enterococci.

Authors:  C Thauvin; G M Eliopoulos; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

View more
  10 in total

1.  Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 2.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Detection of a streptomycin/spectinomycin adenylyltransferase gene (aadA) in Enterococcus faecalis.

Authors:  N C Clark; O Olsvik; J M Swenson; C A Spiegel; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Patterns of antibiotic resistance among enterococcal strains isolated from clinical specimens and food in Poland.

Authors:  T Zareba; W Hryniewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

Review 6.  Virulence of enterococci.

Authors:  B D Jett; M M Huycke; M S Gilmore
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

7.  Increasing problems in the therapy of enterococcal infections.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

8.  Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

9.  Use of the E test to predict high-level resistance to aminoglycosides among enterococci.

Authors:  M L Sanchez; M S Barrett; R N Jones
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

10.  Multilaboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. National Committee for Clinical Laboratory Standards Study Group on Enterococci.

Authors:  J M Swenson; M J Ferraro; D F Sahm; N C Clark; D H Culver; F C Tenover
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.